|Bid||286.00 x 2200|
|Ask||300.26 x 1000|
|Day's Range||298.70 - 303.51|
|52 Week Range||271.37 - 442.00|
|Beta (3Y Monthly)||0.87|
|PE Ratio (TTM)||16.67|
|Earnings Date||Nov 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||382.68|
TARRYTOWN, N.Y. , Oct. 18, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management presentations as follows: Credit Suisse 28 th Annual Healthcare Conference at 10:00 ...
Undervalued stocks are nothing new on Wall Street. And Goldman Sachs making a bullish call to defend a company's shares is not exactly news either. But combine the two and add in price charts that confirm a bottom, and it's clear that there's plenty of potential in some underloved stocks. Specifically, I'm talking about the diversified and superior potential in American Airlines (NASDAQ:AAL), Under Armour (NYSE:UAA) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).There are bulls in investing and then there's Goldman Sachs. One of the market's most storied investment firms certainly maintains reasons for being generally optimistic in its market calls. That's not to say Goldman isn't making prop side bets or that it's always bullish. But when it comes to paying customers, underwriting and the likes, a bull market is good for business.Given how this well-oiled machine operates, a buy recommendation from Goldman isn't exactly a rarity. Nevertheless, when the firm's chief U.S. strategist acknowledges major market headwinds, but sees superior upside potential in several undervalued stocks -- such as Netflix (NASDAQ:NFLX) and Freeport-McMoRan (NYSE:FCX) -- with 50% or more upside, it's time to take notice.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Tech Stocks to Buy Now for 2025 But from there, we can whittle down that list of names to these three stocks to buy, since they have charts that can actually justify all the fuss. With that said, let's dive a little deeper into what makes AAL, UAA and REGN stock worth a buy. Undervalued Stocks to Buy: American Airlines (AAL)As most investors may be aware, AAL stock has been left behind over the past few years while the broader market has continued to rally to all-time-highs. Shares are also down several percentage points since Goldman's initial call.But now AAL looks ready to take-off!American Airlines' weekly chart has confirmed a large pattern double bottom dating back to 2016 with a smaller variation of this formation. With shares of this undervalued stock also showing a supportive stochastics divergence during the development of the just-completed double bottom, it's time to go long AAL stock with confidence.AAL Stock Strategy: Goldman sees upside potential nearing 60% over the next 12 months for this undervalued stock. Use the failure of the paired double bottoms to contain losses if needed and take initial profits at $35 for a stronger risk-adjusted position. Under Armour (UAA)Under Armour is the next of our undervalued stocks to buy. Shares have been rallying for the last two years since initially falling out of favor with growth investors back in 2016, which was compounded by a series of missteps and earnings disappointments. But while UAA stock has gained ground since bottoming in 2017, as this past summer's price action attests, it hasn't been without incident.The good news is right now the home field advantage on the price chart goes to bullish investors in shares of Under Armour. * 7 Beverage Stocks to Buy Now UAA Stock Strategy: Goldman sees about 65% upside possible for UAA stock. I see diversification, a stop-loss slightly beneath the higher-low pattern low at $17.35 and a bonafide slam dunk if this undervalued stock can capture the firm's price objective. However, I'd gladly take the opportunity to trim profits along the way and inside the last earnings gap near $25 a share. Regeneron (REGN)Not that I've saved the best for last, but this undervalued stock to buy does happen to have the largest potential for upside according to Goldman. The firm estimates Regeneron has room to run by roughly 79%. What shares also have going for them is a prolonged bearish market of nearly four years. This may have finally bottomed on the monthly price chart.This view of REGN stock reveals shares have just confirmed a fresh lower low pivot within the biotech's downtrend. With the September pivot just narrowly undercutting the last important low from 2018, a double bottom is in place on the monthly chart. Because the pattern also has the backing of a bullish oversold stochastics crossover, this undervalued stock is a name to buy today.REGN Stock Strategy: Use an out-of-the-money bull call spread because of the risks associated with biotechs like REGN stock and its long history of price volatility.I'd also suggest sticking with the chart for exiting and taking profits along the way. Specifically, use $270 for containing downside exposure and $400 - $425 for reducing upside risk.Disclosure: Investment accounts under Christopher Tyler's management currently own positions in Under Armour (UAA) securities and its derivatives but no other securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional market insights and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Beverage Stocks to Buy Now * 10 Groundbreaking Technologies Created by Universities * 5 Semiconductor Stocks Worth Your Time The post 3 Undervalued Stocks to Buy According to Goldman Sachs appeared first on InvestorPlace.
Biogen and Regeneron Pharmaceuticals are most likely among large-cap biotech companies to top Wall Street's third-quarter sales and earnings expectations, an analyst said Friday.
Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]
Dermira (DERM) starts a phase III program for evaluation of its monoclonal antibody candidate, lebrikizumab, in adolescents and adult patients with atopic dermatitis, the most common form of eczema.
TARRYTOWN, N.Y. , Oct. 10, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2019 financial and operating results on Tuesday, November ...
Novartis gained Food and Drug Administration approval Tuesday for an eye-disease treatment called Beovu that could undercut Regeneron Pharmaceuticals' blockbuster medicine, Eylea.
If you're looking for the top healthcare stocks to buy for the long haul, then you need to be focusing on the oncology and cancer-fighting space. The pace of innovation in the oncology sector has been truly breathtaking. Just a few years ago, many forms of cancer went untreated. However, that's not the case at all today. And new therapies are being developed all the time, making some drug stocks great investments now.For example, two different studies in Proceedings of the National Academy of Sciences (PNAS) from Rice University show the depth of new treatments. This includes targeting mitochondria as well as using gold to destroy cancer cells. With innovative approaches like those at Rice University, we're starting to win the fight against cancer.That also makes cancer-fighting firms the stocks to buy today, since all of that innovation costs a pretty penny -- with new cancer drugs being some of the most expensive on the market.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWith that in mind, the various drug stocks have either seen their products rise to blockbuster status or have the potential for future high earnings. The best part is that many of these drugs lie just beyond the reach of regulators' saber-rattling.For investors, this is another perk that makes cancer-fighting stocks truly some of the best stocks to buy for the long haul. There's plenty of potential to keep the growth and cash flows going. * 8 Stocks to Buy Offering Both Dividends and Growth But which stocks in particular stand out in the oncology space? Here are three of the best drug stocks to buy today as these companies continue in the war against cancer. Drug Stocks to Buy: Bristol-Myers Squibb (BMY)Source: Piotr Swat / Shutterstock.com If you're looking for a "sure thing" among the cancer stocks to buy, pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) could be an amazing choice. BMY has had a long history of blockbuster drugs powering its profits and dividends. And now oncology is driving that train, with blockbuster drug Opdivo leading the way.Sales for Opdivo continue to be swift. Last quarter alone, BMY managed to see a big 12% year-over-year increase in sales of the oncology medicine. Right now, Bristol-Myers pulls in nearly $2 billion in quarterly revenues from the drug alone. Even better is that the pharma continues to study how Opdivo can be used in other indications such as in esophageal cancer. This could lead to other revenue opportunities for the blockbuster.But the real reason why BMY could be a top cancer stock to buy comes down to its pending buyout of Celgene (NASDAQ:CELG). CELG comes with a rich cancer-fighting portfolio, including blockbusters Revlimid, Yervoy and Pomalyst. Adding these to BMY's umbrella creates a real powerhouse in the space. And when you combine both firms' pipelines of new drugs, you really are looking at one of the biggest cancer-fighting stocks on the planet.Meanwhile, BMY's portfolio of non-cancer drugs continues to churn out steady revenue as well. With nearly $30 billion in cash on its balance sheet and a hefty 3.24% dividend, Bristol-Meyers could be one of the best-proven winners in the oncology sector. Exact Sciences (EXAS)Source: Shutterstock In order to treat cancer, you need to detect it. And the earlier you can do that, the greater the chances of survival increase and the ability to fight it is easier. This is why Exact Sciences (NASDAQ:EXAS) could be a great pick for investors that are interested in promising drug stocks to buy.Ask anyone who has ever undergone a colonoscopy about their experience and there's a good chance they'll mention it was miserable. Because of this, colorectal cancer often goes untreated until it's too late. This makes the cancer variety the second-deadliest cancer in America. However, this is where EXAS comes in.The firm makes a diagnostic test called Cologuard, which patients can do at home via a small sample. Detection rates are nearly as good as an old-fashioned colonoscopy. This makes it a big win for both doctors and patients. And Exact Sciences has the sales growth to prove it. During its last reported quarter, EXAS managed to generate $200 million in sales from Cologuard. That was a 94% year-over-year increase in sales and a 93% jump in total test volumes.The real win is that huge jump doesn't cover the total addressable market for colorectal cancer detection nor does it include recent Food and Drug Administration wins to allow EXAS to sell Cologuard to younger age brackets.Perhaps the biggest news for EXAS could be its pending merger with rival Genomic Health (NASDAQ:GHDX). GHDX provides similar tests for the detection of breast and prostate cancer. The deal would unite two fast-growing firms under one banner. * 7 Next-Generation Healthcare Stocks to Buy For investors, that could be the ultimate win in the fight against cancer and that makes EXAS one of the top stocks to buy in the space. Bluebird Bio (BLUE)Source: Shutterstock On the surface, biotech Bluebird Bio (NASDAQ:BLUE) doesn't seem like a cancer-fighting stock. The firm is a gene-editing player whose first commercial drug -- Zynteglo -- is used in the treatment of rare blood disease, transfusion-dependent beta-thalassemia (TDT). Additionally, BLUE counts sickle cell and adrenoleukodystrophy treatments among its pipeline.But BLUE could be one of the more promising clinical-stage cancer-fighting stocks to buy. And that comes down to CAR-T. Chimeric antigen receptor T therapies use patients' own immune cells to go and attack their cancer. It's all cutting-edge stuff and Bluebird is one of the leaders. BLUE touts development deals with both Celgene and Regeneron Pharmaceuticals (NASDAQ:REGN) to use CAR-T to target multiple myeloma.So far, over the last two years, the results have been pretty impressive for lesser mentioned drug stock. Phase III trial data for its lead cancer candidate bb2121 should be released soon and BLUE and CELG estimate that approval for the medication could come in 2020. The approval should propel Bluebird to the upper echelon of drug stocks to buy. Yet, the stock has traded lower on commercial development issues related to Zynteglo.However, with more than $1.5 billion in cash, a huge potential cancer-fighting win and an overall rich pipeline, BLUE stock could be a great stock to buy for investors who are OK with taking a risk.At the time of writing, Aaron Levitt held a long position in the iShares Nasdaq Biotechnology ETF (IBB) -which holds CELG, REGN and BLUE. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Important IPO Stocks to Watch for the Long Run * 7 High Volatility Stocks to Buy as the Market Rebounds * 7 Dow Jones Industrial Average Stocks to Sell The post 3 Cancer-Fighting Drug Stocks to Buy Right Now appeared first on InvestorPlace.
Schleifer Leonard S. became the CEO of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in 1988. This report will, first...
While the S&P 500 is up nearly 19% heading into the final quarter of the year, biotech stocks are badly lagging the market, punishing the performance of many ETFs and other funds holding shares of companies such as Biogen (BIIB), Regeneron Pharmaceuticals Inc. (REGN), BioMarin Pharmaceutical Inc. (BMRN), Gilead Sciences Inc. (GILD), Vertex Pharmaceuticals Inc. (VRTX), and Alexion Pharmaceuticals Inc. (ALXN). The increasingly bearish sentiment is reflected in six consecutive weeks of outflows from biotech funds, amounting to about $2.1 billion, and marking the longest stretch of continuous outflows in nearly two years, as outlined by Barron’s. Weakness in the biotech sector has caused a long list of ETFs to fall sharply from their highs in the last few months, including the giant iShares Nasdaq Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and Invesco Dynamic Biotechnology & Genome ETF (PBE), just to name a few.
Pfizer's (PFE) investigational eczema candidate abrocitinib meets all co-primary and secondary endpoints as a monotherapy in the second pivotal late stage study.
Investors are beginning to doubt Regeneron Pharmaceuticals' research prowess, an analyst said Tuesday, noting Regeneron stock has slid 34% since March. Year-to-date, the stock has lost 22%.
Guggenheim analysts upgraded both Sanofi and Regeneron in part because of optimism about an antibody drug that treats a range of diseases on which the two companies have collaborated.
The company's treatment for nasal polyps receives positive feedback from the European Medicines Agency's Committee for Medicinal Products for Human Use.
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Sept. 20, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that The Lancet has published detailed positive results from two Phase 3 trials evaluating the safety and efficacy of Dupixent® (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps (CRSwNP) despite previous treatment with surgery and/or systemic corticosteroids. Results published in The Lancet demonstrated that adding Dupixent to the standard-of-care corticosteroid nasal spray reduced nasal polyp size and nasal congestion severity (co-primary endpoints). Dupixent also reduced chronic sinus disease associated with nasal polyps and improved sense of smell.
TARRYTOWN, N.Y. and PARIS, Sept. 20, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dupixent® (dupilumab) in a third indication. The CHMP recommended Dupixent be approved as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.